Interview with Dan Goldberger, CEO and Director at electroCore

Medical Device News Magazine: Mr. Goldberger, how does your gammaCore portable prescription device differ from the prescription medications and IV treatments for migraines? (electoCore).

Mr. Goldberger: GammaCore differs from prescription medications and IV treatments for migraines because it is a nerve stimulator, not a pharmaceutical, and has a tremendous safety profile. It is a very safe technology that can be used instead of or in addition to traditional pharmaceutical solutions to treat headaches and migraines. It does not suffer from the limitations of various pharmaceuticals in terms of dosing and contraindications, drug interactions, and side effects.

Most of our patients tell us they get relief within moments of energizing the device instead of waiting for 30 minutes to an hour when they take a pill. So, no pills, no injections—just relief. Our e-commerce platform and telehealth solutions offer a portable handheld personal use device. It fits in well with the trends toward telehealth and self-care.

Medical Device News Magazine: Your device is based upon the use of the Vagus Nerve. What does the Vagus Nerve offer for patient therapy?

Mr. Goldberger: Our device delivers a safe amount of electrical energy non-invasively. The vagus nerve travels with the carotid artery through the neck, so we instruct people to place our device over the carotid artery. The nerve stimulation is programmed to take two minutes. The method of action has to do with how the vagus nerve transmits information to the brain which determines pain and the management of pain. It also transmits signals differently to the body’s major organ systems and regulates the inflammatory response, which is an essential component of what we perceive as headache pain.

Medical Device News Magazine: Is the gammaCore device scalable for additional therapies?

Mr. Goldberger: In January of this year, we announced that the FDA had granted us breakthrough designation for treating post-traumatic stress disorder (PTSD). We are collaborating with the VA hospital system and DARPA, THE Defense Research Grant facility, to bring our PTSD therapy to the market. Not far behind that, NIDA, the National Institute for Drug Abuse, has been sponsoring work using our technology to treat the symptoms of withdrawal from substance abuse, especially for the first week or two of an inpatient substance abuse program. We are excited about applying our technology that is being pulled forward by NIDA and its various initiatives to respond to the opioid epidemic in this country.

Last year, there was data published about treating the symptoms of Parkinson’s disease and the ability of the therapy to support an earlier discharge of patients after abdominal surgery. We also had data published in February of this year about using our technologies in acute stroke treatment. So, we have a robust pipeline, and I look forward to bringing these additional indications to market in 2023 and beyond.

Medical Device News Magazine: How will your next-generation digital platform advance your med-tech to patients?

Mr. Goldberger: Most recently, we have expanded our patent portfolio to talk about connectivity with a mobile device and digital health applications. We are now working on a next-generation platform that will be app-enabled, communicate to our therapeutic device through an app, and collect remote patient monitoring and therapy data. That could ultimately be part of the reimbursement process for prescribing physicians, which will create a much more encompassing user experience for our patients.

For the first time, consumers can go to our e-commerce site. We always recommend interested patients speak with their physicians first. But if that is not convenient, they can go to our website and click on the button that says “Try gammaCoretm” There’s a simple questionnaire that gets routed to a telehealth professional who will interact with the patient and write a prescription if the patient is a suitable candidate. Thus, we have dramatically improved access to our therapy through the e-commerce platform.

We also have a large and growing number of prescribers, both traditional headache specialists in neurology and a growing number of primary care physicians offering therapy. Parallel with that; we have started to invest in direct-to-consumer awareness campaigns, initially through paid search and social media. We have a few social media influencers now that are talking about us. You will see more of that as we go through the second half of 2022 and into 2023.

Medical Device News Magazine: What promise does electroCore and your gammaCore device hold for the capital markets?

Mr. Goldberger: Although our stock has been negatively affected by the market turmoil, the company is stronger than ever and accelerating.

We have a healthy balance sheet with almost $30 million in current assets as of March 31, 2022. Revenues are growing more than 50% annually, and gross margins have expanded to about 80%. I am very proud of what our team has accomplished in terms of growing the business and being good stewards of the stockholders’ cash. We are fortunate that we have a solid balance sheet. We have more than enough resources to continue to execute our plan for several years to come.





Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Experts Views and Opinions

Last year was one of the worst years ever for cyber attacks on healthcare organizations. According to John Riggi, national advisor for cybersecurity and risk for the American Hospital Association, the number of people affected by attacks broke records, with US federal data indicating that around 106 million people were impacted by a healthcare data breach, more than double when compared to 2022.
Moby Cutter™ is one of the safest surgical wire cutters on the market today! Their medical design team has over 35 years of experience performing surgical procedures in Hospitals, Emergency Rooms and Urgent Care Systems. It has been cleared for commercialization per FDA guidelines and sold as a prescription only (Rx) medical device. Dr. Stanley shares the advantages of the Moby Cutter.
Health systems continue to face ongoing pressures to reduce costs while maintaining quality patient care. With the average operating margin for hospitals at 0.84%, health systems are searching for ways to more effectively manage operating and capital budgets. However, gaps in data often hinder health systems by hiding cost burdens throughout the organization. These hidden costs limit health systems to finding one-time-savings without lasting relief from industry-wide pressures.
Healthcare organizations face many challenges: they must protect patient privacy, deliver quality care, and meet strict regulations. These organizations, which include medical device manufacturers, are trusted to safeguard incredibly sensitive information, a task that carries immense responsibility. Read on to learn what this industry expert has to say.
Dr. Amy Hester writes, "However, while technology has brought about incredible advancements, an essential aspect must not be overlooked—integrating a human touch in healthcare delivery, particularly in the context of falls prevention among veterans." Read to learn more.

By using this website you agree to accept Medical Device News Magazine Privacy Policy